From: Are exhaled nitric oxide measurements using the portable NIOX MINO repeatable?
 | Birth cohort participants* |  | ||
---|---|---|---|---|
 | All participants | Participants with asthma | Non-asthmatic participants | Intervention study participants |
 | (n = 494) | (n = 71) | (n = 401) | (n = 65) |
Age (years), mean (range) | 17.17 (16-18) | 17.21 (16-18) | 17.16 (16-18) | 11 (6-16) |
Sex, no. (%) | Â | Â | Â | Â |
   Male | 251 (50.8) | 36 (50.7) | 207 (51.6) | 38 (58.5) |
   Female | 243 (49.2) | 35 (49.3) | 194 (48.4) | 27 (41.5) |
Hay fever, no. (%) | 183 (37.0) | 49 (69.0) | 125 (31.2) | 56 (86.2) |
Eczema, no. (%) | 82 (16.6) | 24 (33.8) | 56 (14.0) | 38 (58.5) |
Atopy (as defined by skin prick testing), no. (%) ** | 195 (42.1) | 48 (72.7) | 141 (37.3) | 37/42 (88.1) |
FEV 1 (% predicted), mean (SD) | 104.58 (13.22) | 97.34 (15.38) | 105.99 (12.28) | 90.35 (14.57) |
FeNO (ppb), median (interquartile range) *** | 16 (11-31) | 40 (16-74) | 15 (11-25.5) | 35 (13.5-57.0) |
Asthma treatment, no. (%) | Â | Â | Â | Â |
   Inhaled corticosteroids | NA | 34 (47.9) | NA | 65 (100) |
   Short-acting bronchodilators |  | 46 (64.8) |  | 65 (100) |
   Long-acting bronchodilators |  | 12 (16.9) |  | 48 (73.8) |
   Montelukast |  | 1 (1.4) |  | 36 (55.4) |
   Theophylline |  | 0 (0) |  | 3 (4.6) |